A new path in DNA-powered medicine.
An oncology-focused biotechnology company leveraging its innovative DNAbilize® platform technology to deliver DNA therapeutics directly to cancer cells
An oncology-focused biotechnology company leveraging its innovative DNAbilize® platform technology to deliver DNA therapeutics directly to cancer cells
We are developing targeted cancer treatments that offer effective therapy without harsh side effects so that even the most fragile patients can have tolerable treatment options.
About UsThe company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy.
Learn More
Prognosis for these older cancer patients remains very poor. Bio-Path aims to meet the need that exists for non-toxic therapies for older, fragile cancer patients who are unfit or ineligible for high-dose chemotherapy.
Our pipeline consists of antisense RNAi nanoparticle drugs in clinical development for some of the most lethal blood cancers and solid tumors.
Our Technologies